TABLE 1.
Change from baseline of mean FACE-Q scores used in mid-face and nasolabial fold dermal filler studies
| ARTICLE | Monheit, 2020 Derm Surg 11 | Kaufman-Janette, 2019 JCD12 | Jones, 2020 Derm Surg 13 | Ogilvie, 2020 JCD
14 Niforos, 2019 CCID 15 |
|||||||||||
| PRODUCT | RHA2/ HYC-24L (N=74) | RHA3/ HYC-24L (n=74) | RHA4 vs LGP-HA-L (n= 120) | LGP-HA-L via microcannula (n=60) | VYC-12 (n=127) | ||||||||||
| TREATMENT SITE | NLF | NLF | Multiple sites along midface ± zygomatic | Cheeks, Forehead ± Neck | |||||||||||
| INJECTION TECHNIQUE | Linear threading, multiple serial punctures, fan-like injection | Linear threading, multiple serial punctures, fan-like injection | Microcannula: Linear Ante/Retrograde,Depot, Fanning | Intradermal injection | |||||||||||
| VOLUME USED (MEAN) | RHA2: 1.54 mL HYC-24L: 1.30 mL |
RHA3: 1.52 mL HYC-24L: 1.30 mL |
Initial: RHA4: 1.54mL** LGP-HA-L: 1.42mL |
Retreatment not reported | Initial: 3.0 mL Optional retreatment: 1.6mL |
Initial: 3.6mL Optional retreatment: 2.6mL |
|||||||||
| FOLLOW UP | 64 weeks s/p initial treatment |
64 weeks s/p initial treatment |
24 weeks s/p initial treatment |
64 weeks (s/p initial retreatment) | 8 weeks s/p single treatment |
9 months /p initial/touch up treatment | s/p 1 month Retreat at 9 months (n=62) |
||||||||
| RHA2 | HYC-24L | RHA3 | HYC-24L | RHA4 | LGP-HA-L | RHA4 (75% of subjects) | LGP-HA-L (78.4% subjects) | ||||||||
| CHANGE FROM BASELINE OF MEAN FACE-Q SCORE | SATISFACTION WITH NLF | 33.7 | 34.3 | 35 | 35 | 46.2** | 40.4 | 45** | 38.5 | NR | NR | NR | |||
| NR | NR | NR | NR | NR | 12.2* | 23.7* | |||||||||
| SATISFACTION WITH SKIN | |||||||||||||||
| SATISFACTION WITH OUTCOME (% “SATISFIED” OR “VERY SATISFIED“ WITH RESULTS | >82% of subjects | 93.1%** | 85.1 | 97.1** | 88.6 | 77.3 | NR | NR | |||||||
*Significant (p<0.05) compared to baseline.
**Significantly different compared to LGP-HA-L.
HYC-24L: Juvéderm Ultra ® XC; LGP-HA-L: Large gel particle HA with lidocaine (Restylane-Lyft ®); NLF: Nasolabial Fold; NR: not reported; RHA2
(Teoxane RHA®2), RHA3 (Teoxane, RHA®3), RHA4 (Teoxane RHA®4); VYC-12 (Juvéderm® Volite™ with Lidocaine; Allergan Aesthetics, an AbbVie Company)